Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid Tumors
Latest Information Update: 17 May 2023
At a glance
- Drugs Sotigalimab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Apexigen
- 24 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.